MarketPeel
Insider Trading Intelligence
Pricing
…
CS

Christopher Ryan Sullivan

AVTX
CHIEF FINANCIAL OFFICER · AVALO THERAPEUTICS, INC. · CIK 0001810417
FILING MIX · LIFETIME44%/56%
BUYS
16
SELLS
20
TOTAL VALUE
$2.63M
COMPANIES
1
ACTIVE SINCE
Dec 2021
HOLDINGS NOW
40,773
AVG SELL PX
$18.10
TRADE KIND
SHOWING 36 / 36
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
14 backtested trades · 8 horizons · 50 pending
Forward-return performance of every backtestable P/S trade by Christopher Ryan Sullivan, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d14+71.43%+0.04%+1.89%-1.85%-10.14%—
14d14+85.71%-9.16%+4.59%-0.97%-12.79%—
30d14+71.43%-28.55%+4.86%-41.72%-39.17%—
60d14(6 pending)+50.00%-13.10%+1.20%-20.05%-6.98%—
90d14(8 pending)+0.00%-18.71%+8.08%-26.79%-5.48%—
180d14(12 pending)+0.00%-86.54%-2.75%-83.79%-83.79%—
1y14(12 pending)+0.00%-87.76%+5.42%-93.17%-93.17%—
2y14(12 pending)+0.00%-99.67%+22.26%-121.93%-121.93%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
AVTX · 40,773 shares · as of Jun 10, 2026
0100,000200,000300,000400,00020222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 16 buys / 20 sellsCOVERAGE · 19 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
AVTX
AVALO THERAPEUTICS, INC.
SALE
Chief Financial Officer
138$13.10$1.8K40,773Jun 10, 2026Jun 12, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
39,900——40,323May 21, 2026May 26, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE
Chief Financial Officer
18,606——168,094May 7, 2026May 11, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
18,606$24.12$448.8K423May 7, 2026May 11, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
18,606$9.88$183.8K19,029May 7, 2026May 11, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE
Chief Financial Officer
47,000——116,000May 6, 2026May 7, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,700$20.76$56.1K18,542May 6, 2026May 7, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
9,219$21.37$197.0K9,323May 6, 2026May 7, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
13,834$18.55$256.7K33,589May 6, 2026May 7, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,900$22.57$200.9K423May 6, 2026May 7, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
12,347$19.28$238.1K21,242May 6, 2026May 7, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
47,000$8.04$377.9K47,423May 6, 2026May 7, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,457$13.23$111.9K423Apr 30, 2026May 1, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,458$13.09$110.7K8,880Apr 29, 2026May 1, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
6,200$17.02$105.6K19,118Apr 2, 2026Apr 3, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,780$17.57$31.3K17,338Apr 2, 2026Apr 3, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,479$16.83$125.8K25,318Apr 1, 2026Apr 3, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
500$15.86$7.9K32,797Apr 1, 2026Apr 3, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
24,200——41,538Mar 28, 2026Mar 31, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE
Chief Financial Officer
8,241$13.89$114.5K33,297Mar 28, 2026Mar 31, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE
Chief Financial Officer
24,200——24,200Mar 28, 2026Mar 31, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
105,000——105,000Feb 26, 2026Mar 2, 2026 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE
Chief Financial Officer
155$4.10$63617,338Dec 10, 2025Dec 12, 2025 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
24,200——24,206Mar 28, 2025Apr 1, 2025 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE
Chief Financial Officer
7,285$8.46$61.6K16,921Mar 28, 2025Apr 1, 2025 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
SALE
Chief Financial Officer
24,200——48,400Mar 28, 2025Apr 1, 2025 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
163,000——163,000Jan 28, 2025Jan 30, 2025 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
186,700——186,700Aug 13, 2024Aug 14, 2024 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
72,600——72,600Aug 13, 2024Aug 14, 2024 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
511$3.42$1.7K1,262Jun 9, 2023Jun 12, 2023 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
40,000——40,000May 15, 2023May 16, 2023 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
40,000——40,000Feb 13, 2023Feb 15, 2023 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——25,000Oct 5, 2022Oct 5, 2022 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
400,000——400,000Mar 8, 2022Mar 10, 2022 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,000——50,000Mar 8, 2022Mar 10, 2022 ↗View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASE
Chief Accounting Officer
955$1.57$1.5K9,004Dec 10, 2021Dec 14, 2021 ↗View →
Other insiders · AVTX
Loading peer insiders…
About this filer
CIK 0001810417
ROLE
Chief Financial Officer
PRIMARY
AVTX
COMPANIES
1
ACTIVE SINCE
Dec 2021
MARKETPEEL · /INSIDER/0001810417DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback